PLRZ: POLYRIZON LTD Stocks News on August 3, 2025

PLRZ

GlobeNewswire

2 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

PLRZ

MT Newswires

2 months ago

Polyrizon Receives Nasdaq Delisting Notice

PLRZ

GlobeNewswire

2 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

PLRZ

GlobeNewswire

2 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

PLRZ

GlobeNewswire

3 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

PLRZ

MT Newswires

3 months ago

Top Midday Gainers

PLRZ

MT Newswires

3 months ago

Polyrizon Shares Surge After Dropping Reverse Stock Split Plan

PLRZ

GlobeNewswire

3 months ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

PLRZ

MT Newswires

4 months ago

Polyrizon Gets Nasdaq Noncompliance Notice Over Minimum Bid Price Rule

PLRZ

GlobeNewswire

4 months ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

PLRZ

GlobeNewswire

4 months ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

PLRZ

GlobeNewswire

4 months ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

PLRZ

GlobeNewswire

4 months ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

PLRZ

GlobeNewswire

4 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

PLRZ

GlobeNewswire

4 months ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Psychedelic: atai Life Sciences, NRx report quarterly results

PLRZ

TipRanks

4 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

PLRZ

GlobeNewswire

4 months ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

PLRZ

MT Newswires

5 months ago

Polyrizon Signs Letter of Intent With Biotech Firm for Use of Its Intranasal Drug Delivery Platform

PLRZ

GlobeNewswire

5 months ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

PLRZ

GlobeNewswire

5 months ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

PLRZ

GlobeNewswire

5 months ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

PLRZ

GlobeNewswire

5 months ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

PLRZ

GlobeNewswire

6 months ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

PLRZ

GlobeNewswire

6 months ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

PLRZ

GlobeNewswire

7 months ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

PLRZ

GlobeNewswire

7 months ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

PLRZ

GlobeNewswire

8 months ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

PLRZ

GlobeNewswire

8 months ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

PLRZ

GlobeNewswire

8 months ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

PLRZ

ACCESSWIRE

9 months ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

PLRZ

GlobeNewswire

9 months ago

Latest POLYRIZON LTD (PLRZ) News on August 3, 2025

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Receives Nasdaq Delisting Notice

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Top Midday Gainers

Polyrizon Shares Surge After Dropping Reverse Stock Split Plan

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Gets Nasdaq Noncompliance Notice Over Minimum Bid Price Rule

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Psychedelic: atai Life Sciences, NRx report quarterly results

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Polyrizon Signs Letter of Intent With Biotech Firm for Use of Its Intranasal Drug Delivery Platform

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Share on Social Networks: